Liquidia Technologies, which recently published positive Phase 1 results for its LIQ861 treprostinil DPI for the treatment of pulmonary arterial hypertension, has named former Quintiles executive Kevin Gordon as President and Chief Financial Officer. Gordon was most recently Executive VP and Chief Operating Officer of Quintiles. He held various business development positions at Teleflex over two decades and serving as Executive VP and CFO before leaving for Quintiles in 2010.
Gordon commented, “I am excited to join the Liquidia team at such a pivotal moment in the company’s history. I am impressed with the potential of Liquidia’s PRINT technology and the company’s internal pipeline, with its lead product candidate, LIQ861, in a phase 3 for the treatment of pulmonary arterial hypertension. I look forward to contributing to the efforts of the Liquidia team to advance our programs.”
Liquidia CEO Neal Fowler said, “Kevin is a valuable addition to our leadership team, bringing over 30 years of operational and financial accomplishments to Liquidia. We look forward to his meaningful contributions as we continue to build a fully integrated biopharmaceutical company focused on transforming the lives of patients through the development and commercialization of human therapeutics using our proprietary PRINT technology.”
Read the Liquidia Technologies press release.